FIMALAC : 2016 Results I)   Condensed consolidated

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
99
FIMALAC : 2016 Results

I)   Condensed consolidated income statement

When analyzing the presentation of the comparative income statement it is important to take into account (i) the significant contribution from equity-accounted companies, notably Fitch Group (20%-owned by Fimalac) and Barrière (40%-owned) and (ii) the substantial non-recurring capital gains recognized in 2015.

(in € millions)        
    2015   2016
         
EBITDA(*)   13.1   26.5
Depreciation, amortization, provisions and other   (20.3)   (62.5)
Other non-recurring expenses, net   (113.5)   (17.0)
Net financial income/(expense)   (17.5)   9.1
Income tax   10.1   7.2
Share of profit of equity-accounted investees   56.7   93.5
Capital gain on sale of 30% of Fitch Group   1,652.9    
Other income   1.5   3.8
Profit attributable to equity holders of the parent   1,583.0   60.6

(*)    EBITDA: earnings before interest, tax, depreciation, amortization and provisions.

Profit attributable to equity holders of the parent totaled €60.6 million in 2016. There were no material asset sales during the year, whereas the profit figure for 2015 included gains of (i) €1,652.9 million on the sale of 30% of Fitch Group that took place in March 2015 and (ii) €27.4 million (recorded as financial income) arising on the sale of the shares held by the Group in NextRadioTV. In addition, non-recurring expenses were recognized in 2015 for asset write-downs and contingency provisions and although there were similar non-recurring expenses in 2016 they represented a lower amount.

Fitch , which is accounted for by the equity method on a 20% basis, contributed €64.2 million to consolidated profit in 2016 (€40.1 million in 2015), reflecting a strong operating performance and the positive impact of non-recurring items. The contribution of 40%-owned Barrière , which is also accounted for by the equity method, rose sharply to €29.5 million from €16.6 million in 2015, due to non-recurring gains on sales or liquidations of non-strategic assets.

Fimalac's Digital sector, organized around Webedia, continued to expand its operations during the year, with 2016 revenue of €210.1 million coming in ahead of the target originally set in the business plan. Conversely, growth for the Group's Entertainment sector (2016 revenue contribution of €112.6 million) was hampered by lower audience numbers at live entertainment events, notably due to the terrorist attacks in France.

  1. Condensed consolidated balance sheet
(in € millions)   Dec. 31, 2015   Dec. 31, 2016
         
Assets        
Goodwill, intangible assets and property and equipment   905   1,594
Equity-accounted investees   392   421
Other non-current assets   157   193
Other current assets   192   339
Cash and cash equivalents   1,482   709
    3,128   3,256
Equity and liabilities        
Total equity   2,203   2,040
Long-term debt   431   640
Other non-current liabilities   61   55
Short-term debt   258   253
Other current liabilities   175   268
    3,128   3,256

The main changes in the consolidated balance sheet at December 31, 2016 compared with December 31, 2015 stemmed from the three specific transactions described below.  In June 2016, the Group acquired an office building in New York for $527 million (excluding transaction fees and transfer taxes). Out of this total, $250 million was raised through borrowings and the remaining amount was financed using Fimalac's own resources. Also in June 2016, the Group purchased an office building in Levallois-Perret, France, which is currently leased to Webedia. The cost of this acquisition came to €106 million (excluding transaction fees and transfer taxes), €70 million of which was financed by borrowings and the remainder by the Group's cash.  In May 2016, Fimalac bought back 6.3% of its own shares, through a simplified public offer, for approximately €172 million (excluding transaction costs), which it paid in cash. This transaction - and the payment of the 2015 dividend - accounted for some of the year-on-year decrease in total equity. As well as carrying out the above three specific transactions, in 2016 Fimalac pursued the development of its Digital sector and, to a lesser extent, its Entertainment sector.

  1. Recommended dividend of €2.10 per share

At its meeting held today, Fimalac's Board of Directors decided that at the Annual Shareholders' Meeting to be held on June 13, 2017 it will recommend a dividend payment of €2.10 per share for the year ended December 31, 2016, unchanged from the 2015 dividend.

  IV)  Cancellation of treasury stock

 Also at its meeting held today, the Board decided to reduce the Company's capital (made up of 26,140,000 shares) by cancelling 1,440,000 treasury shares, representing 5.51% of the total capital. As a result of this capital reduction, the Company's share capital is now made up of 24,700,000 shares.

This type of share cancellation and consequent capital reduction is standard practice when treasury shares have been held for a certain period. Following the operation, the majority of the Group's treasury shares (excluding those held in connection with the liquidity agreement) have been cancelled because out of the 1,700,000 Fimalac shares bought back through the above-mentioned simplified public offer carried out in May 2016, 780,000 had already been cancelled on June 15, 2016.

Consequently, the Company's treasury shares now represent 0.18% of its new share capital. Groupe Marc de Lacharrière - Fimalac's majority shareholder - holds 93.62% of the Company's new capital, acting in concert principally with Marc Ledreit de Lacharrière, and the free float represents 6.20%.

Paris, April 6, 2017

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...af9dc932f8

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elong Kicks Off Central Asia Strategy with Almaty Launch

Updated Category News Views 70

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

Continue Reading
AptarGroup Faces Investigation: Shareholder Stakes High

Updated Category News Views 89

AptarGroup Directors Under Investigation Every seasoned investor knows the market isn’t just sunshine and rainbows. Lately, the storm clouds have gathered over AptarGroup, Inc. (NYSE: ATR). Out of nowhere comes Purcell & Lefkowitz LLP, announcing a shareholder investigation that sends shivers down the spines of those who've put their money on this packaging...

Continue Reading
24X Partners with Standard Chartered for Crypto Leap

Updated Category News Views 86

24X Steps Up the Game with Crypto Addition You gotta give it to 24X—they're not just twiddling their thumbs in the background. These folks in Bermuda have snagged another feather in their cap by expanding their partnership with heavyweight Standard Chartered, bringing Bitcoin and Ethereum into the mix. We're talking big moves here as 24X becomes the first to offer...

Continue Reading
Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 191

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Sino Biological Boosts AI Protein Discovery Efficiency

Updated Category News Views 37

Dissecting the Bridge Between AI and Biology In the cutthroat world of biotech, every second counts. Sino Biological is taking a good hard look at bridging AI and practical applications with their shiny new 4RISE™ solution. The stakes couldn't be higher—turning computer-generated protein ideas into lab-tested realities is no small feat. And believe me, researchers...

Continue Reading
VT Markets Unites Trading and Drama in New Finale

Updated Category News Views 76

Trading Meets Reality Show Drama Just when you thought you'd seen it all in the trading world, VT Markets rolls out a new spectacle. They're launching the Gold Cup 2026, an unscripted reality show stuffed with enough drama and tension to keep any trader on the edge of their seat. This isn't your run-of-the-mill trading competition; this is an injection of pure adrenaline...

Continue Reading
Poland's Economic Boom: A Case for Freedom and Growth

Updated Category News Views 60

Poland's Remarkable Journey to Economic Power Freedom, they say, fuels progress—and Poland stands as a pulsating testament to that very idea. Thirty-odd years ago, shedding the chains of Soviet-imposed communism, Poland was all systems go, taking the wheel of its own destiny. For the first time, Polish innovation and industry were unleashed, paving the road toward...

Continue Reading
Quantinuum & RIKEN Propel Japan's Quantum Leap Forward

Updated Category News Views 81

Quantum Computing: Japan's Bold New Frontier Quantum computing's buzz is getting louder, and the big players like Quantinuum and RIKEN ain't sitting on their hands. They've rolled up their sleeves to ramp up Japan's quantum-AI supercomputing game with the recent beef-up of Quantinuum's Reimei to its H2 system, putting Japan at the cutting edge of hybrid computing. The...

Continue Reading
AION Labs Elevates Leadership, Eyes New R&D Horizons

Updated Category News Views 70

Setting New Standards in Pharma Innovation The air in Rehovot, Israel might be filled with more than just technological aspirations, thanks to AION Labs stepping up its leadership game. This venture studio doesn't seem content to rest on its laurels. Nope, it's diving headlong into the deeper end of pharma R&D, scouting out fresh tech territories like quantum computing...

Continue Reading
1-800Accountant Secures Global Win in Tax Services

Updated Category News Views 53

Another Feather in the Cap for 1-800Accountant You don’t get to be at the top of your game without turning a few heads. And 1-800Accountant has done just that, snagging the Fall 2026 Clutch Global Award for their expertise in the accounting universe. The Importance of Listening In this day and age, businesses large and small are realizing that the voice of the client is...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Fundraising Campaign to Restore Food Bank Services

Updated Category News Views 160

Transforming Community Support Through Art and Action In the wake of devastating wildfires that impacted a significant area, a new initiative is taking shape to assist those affected. This unique campaign combines the power of art and activism to address an urgent community need: the restoration of a food bank that has served countless families over the past two decades....

Continue Reading
OYO Expands Horizons with Acquisition of G6 Hospitality

Updated Category News Views 67

OYO Acquires G6 Hospitality: A Major Strategic Move In a significant development, Oravel Stays, the parent company of OYO, has announced its acquisition of G6 Hospitality from Blackstone Real Estate for $525 million. This all-cash deal aims to strengthen OYO's presence in the U.S. hospitality industry. Growing Presence in the United States Since diving into the U.S....

Continue Reading
Dizal's Sunvozertinib Receives FDA Priority Review for NSCLC

Updated Category News Views 262

FDA's Priority Review of Sunvozertinib: A Game Changer for NSCLC Dizal is making headlines with the announcement that the U.S. Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application (NDA) for Sunvozertinib. This oral EGFR inhibitor holds the promise of offering a significant treatment option for patients suffering from...

Continue Reading
Deep Dive into Masimo Corporation's Ongoing Legal Troubles

Updated Category News Views 294

Masimo Corporation Under Scrutiny Recently, the spotlight has turned to Masimo Corporation (NASDAQ: MASI) as investigations unfold regarding potential misconduct among its leadership. The inquiry is spearheaded by Charles C. Foti, Jr., a former Attorney General of Louisiana and partner at Kahn Swick & Foti, LLC. Revenue Shortfalls and Investor Concerns The company faced a...

Continue Reading
PMV Pharmaceuticals Unveils Promising Monotherapy Data for Solid Tumors

Updated Category News Views 471

Exciting Developments in Cancer Treatment In the realm of precision oncology, PMV Pharmaceuticals continues to lead the charge with groundbreaking research that shines a spotlight on novel therapies. Today, the company has presented updated interim data that promises to reshape the treatment landscape for patients dealing with advanced solid tumors, particularly those...

Continue Reading